• 0-1=low risk
• 2= moderate risk
• 3+ = high risk

Provides interpretation of results and recommendation on whether to start anticoagulation therapy.

• 0=low risk
• 1-2 = intermediate risk
• 3=high risk

*Important to compare to bleeding risk*

• For males: score 0=low risk, 1=low-moderate risk & 2+ is moderate to high risk
• For females: score 1=low risk, 2=low-moderate risk & 3+ is moderate to high risk

Provides recommendation on whether to start anticoagulation therapy.

*Important to compare to bleeding risk

Although there is no statistical difference between CHA₂DS₂-VASc and CHADS₂ , CHA₂DS₂-VASc is preferred.

• Why? Incorportates more risk factors (ex. Different age ranges, sex)

If a patient is considered “low risk”, CHA₂DS₂-VASc can better assess the need for anticoagulation (ex. Patient may have a score of 0 with CHADS₂ but CHA₂DS₂-VASc may be different).

• Updated regularly (last update May 2023)
• Provides absolute and relative risk reduction with specific drug therapies
• Information presented in both table and bar graph form

If you are interested in the interpretation of CHA₂DS₂-VASc and HAS-BLED scores, it is best to use their individual scoring tools.

• Clinical investigations of condition (risk factors, classification, signs and symptoms)
• Rate and rhythm management algorithms (acute and chronic)
• Stroke prevention treatment
• Dosing
  • Renal adjustments
  • Special populations
    • Ex. Apixaban 2.5mg BID if 2+ criteria
      • 80+ years old
      • 60kg of less
      • SCr 133umol/L +
• Special considerations based on co-morbidities (ex. AF + CAD)